Catalog No.
DPE40102
Species reactivity
Human
Isotype
Biosynthetic peptide.
Target
GLP-1 receptor, Glucagon-like peptide 1 receptor, GLP1R, GLP-1-R, GLP-1R, Gastric inhibitory polypeptide receptor, GIPR, GIP-R, Glucose-dependent insulinotropic polypeptide receptor
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by HPLC.
Purification
Purified by HPLC.
Accession
P43220 & P48546
Applications
Research Grade Biosimilar
Form
Lyophilized
Reconstitution
Reconstitute in sterile water for a stock solution.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAS: 2023788-19-2
[Weight reduction with incretin mimetics-Opportunities and risks]., PMID:40514554
[Arthritis secondary to tirzepatide. Case report]., PMID:40513494
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes., PMID:40512543
Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies., PMID:40512404
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology., PMID:40512113
Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity., PMID:40512029
Key takeaways from the updated multidisciplinary European MASLD guidelines., PMID:40510733
Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes., PMID:40510603
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:40510020
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs., PMID:40507574
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies., PMID:40507553
Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data., PMID:40503067
Cardiovascular benefits of Tirzepatide: A breakthrough in cardio-metabolic care., PMID:40500849
Tirzepatide: a novel therapeutic approach for Alzheimer's disease., PMID:40498212
The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment., PMID:40497223
Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide., PMID:40491599
Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status., PMID:40491239
Tirzepatide differentially affects body weight in mice and humans., PMID:40490496
Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial., PMID:40490415
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis., PMID:40489581
Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea., PMID:40487675
Tirzepatide Affect Sexual Function in Women: Case Report., PMID:40487373
Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study., PMID:40486301
Review of Article: Wu JY, Tu WL, Yu T, Liao KM, Lin YM. Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract. 2025;222:112,083., PMID:40484580
GLP-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate PAD., PMID:40484062
Characteristics and Treatment Patterns of People Without Type 2 Diabetes Diagnoses Who Use Tirzepatide in the United States., PMID:40480878
Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial., PMID:40478570
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis., PMID:40471293
Diabetic ketoacidosis in a patient with type I diabetes treated with tirzepatide., PMID:40471291
GLP-1-based medications: Mechanisms involved in obesity treatment., PMID:40466247
Tirzepatide for weight reduction in people without diabetes., PMID:40461177
The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure., PMID:40458830
A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait., PMID:40458827
Dual Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist-Associated Thyroiditis: A Case Report of Thyroid Dysfunction Following Tirzepatide Use., PMID:40458348
Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study., PMID:40456414
Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity., PMID:40452343
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists., PMID:40447342
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis., PMID:40444045
Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale., PMID:40443633
[Glucagon-like peptide 1 agonists : the fourth pillar of nephroprotection in type 2 diabetes]., PMID:40443145
[Nutritional management of type 2 diabetes with GLP-1 and GLP-1/GIP agonists]., PMID:40443143
Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study., PMID:40437798
Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models., PMID:40430489
The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials., PMID:40430487
The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort., PMID:40426877
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review., PMID:40422561
Tirzepatide for Obstructive Sleep Apnea: A Novel Therapeutic Promise and the Perioperative Considerations., PMID:40420878
Off-label GLP-1 weight-loss medicine use among online bodybuilders: Folk pharmacology, risk and harm reduction., PMID:40418873
Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy., PMID:40415172
Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System., PMID:40413246
For research use only. Not for human or drug use.
